FABP4 Antibody

FABP4 Polyclonal Antibody for IF, IHC, WB, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse, rat

Applications

WB, IHC, IF, ELISA

Conjugate

Unconjugated

Cat no : 15872-1-AP

Synonyms

A FABP, AFABP, ALBP, aP2, FABP4, Fatty acid binding protein 4



Tested Applications

Positive WB detected inrat skeletal muscle tissue, human heart tissue, mouse skeletal muscle tissue, mouse small intestine tissue
Positive IHC detected inhuman cervix tissue, human skin tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive IF detected inmouse adipose, HUVEC cells

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:500-1:1000
Immunohistochemistry (IHC)IHC : 1:20-1:200
Immunofluorescence (IF)IF : 1:20-1:200
Sample-dependent, check data in validation data gallery

Product Information

15872-1-AP targets FABP4 in WB, IHC, IF, ELISA applications and shows reactivity with human, mouse, rat samples.

Tested Reactivity human, mouse, rat
Cited Reactivity human, mouse
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen FABP4 fusion protein Ag8631
Full Name fatty acid binding protein 4, adipocyte
Calculated molecular weight 132aa,15 kDa
Observed molecular weight 15 kDa
GenBank accession number BC003672
Gene symbol FABP4
Gene ID (NCBI) 2167
Conjugate Unconjugated
Form Liquid
Purification Method Antigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

Fatty acid binding protein (FABP) 4 is a member of the FABP family which abundantly expressed, fatty acid carrier proteins. FABPs are capable of binding a variety of hydrophobic molecules such as long-chain fatty acids and are important for their uptake and intracellular trafficking. It was first identified as an adipocyte-specific protein, important for the maintenance of lipid and glucose metabolism. It is also detected in macrophages, where it participates in regulating inflammation and cholesterol trafficking via NFκB and PPAR. In more recent studies, FABP4 has been found in a variety of endothelial cells, where it has been identified as a target of VEGF and a regulator of cell proliferation and possibly angiogenesis. Pathologically, FABP4 has been associated with the development of metabolic syndrome, diabetes and cancer and vulnerability of atherosclerotic plaques. FABP4 has been identified as a novel prognostic factor for both adverse cardiovascular events and breast cancer.

Protocols

Product Specific Protocols
WB protocol for FABP4 antibody 15872-1-APDownload protocol
IHC protocol for FABP4 antibody 15872-1-APDownload protocol
IF protocol for FABP4 antibody 15872-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
human,mouseWB,IHC

Cancers (Basel)

Deregulating the CYP2C19/Epoxy-Eicosatrienoic Acid-Associated FABP4/FABP5 Signaling Network as a Therapeutic Approach for Metastatic Triple-Negative Breast Cancer.

Authors - Maria Karmella Apaya
mouseIF

PLoS Biol

Single-cell mapping reveals new markers and functions of lymphatic endothelial cells in lymph nodes.

Authors - Noriki Fujimoto
mouseWB

Lipids Health Dis

Dlgap1 negatively regulates browning of white fat cells through effects on cell proliferation and apoptosis.

Authors - Ju Zhang

Am J Physiol Cell Physiol

Human Adipocytes from the Subcutaneous Superficial Layer have Greater Adipogenic Potential and Lower PPAR-γ DNA Methylation Levels than Deep Layer Adipocytes.

Authors - Kentaro Kosaka
humanWB

Int J Obes (Lond)

miR-20a regulates adipocyte differentiation by targeting lysine-specific demethylase 6b and transforming growth factor-β signaling.

Authors - J Zhou
humanIHC

Eur Heart J

Adipocyte fatty acid binding protein in atherosclerotic plaques is associated with local vulnerability and is predictive for the occurrence of adverse cardiovascular events.

Authors - Peeters Wouter W